Search research articles
Contact Us
Filters
Showing results (41-50 of 170) with videos related to
Page
of 17
Sort By:
Clinical & Developmental Immunology
|
July 24, 2013
JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?
Roberta Antonia Diotti, Akira Nakanishi, Nicola Clementi, et al.
International Journal of Molecular Sciences
|
June 19, 2024
Anti-HIV Humoral Response Induced by Different Anti-Idiotype Antibody Formats: An In Silico and In Vivo Approach
Valeria Caputo, Ilaria Negri, Louiza Moudoud, et al.
Journal of Medical Virology
|
March 9, 2023
Smallpox vaccination-elicited antibodies cross-neutralize 2022-Monkeypox virus Clade II
Elena Criscuolo, Benedetta Giuliani, Roberto Ferrarese, et al.
Antiviral Research
|
July 19, 2011
The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir
Filippo Canducci, Elisa Rita Ceresola, Diego Saita, et al.
AIDS Research and Human Retroviruses
|
January 13, 2004
Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure
Enzo Boeri, Nicola Gianotti, Filippo Canducci, et al.
The Journal of Antimicrobial Chemotherapy
|
December 21, 2002
Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients
Stefania Paolucci, Fausto Baldanti, Maurizio Zavattoni, et al.
The Journal of Infectious Diseases
|
October 11, 2011
Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir
Filippo Canducci, Elisa R Ceresola, Enzo Boeri, et al.
Virology
|
September 8, 2004
Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection
Roberto Burioni, Nicasio Mancini, Silvia Carletti, et al.
Viruses
|
June 24, 2022
Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2
Elena Criscuolo, Benedetta Giuliani, Davide Ferrari, et al.
Clinical Microbiology Reviews
|
April 1, 2021
Viral Respiratory Pathogens and Lung Injury
Nicola Clementi, Sreya Ghosh, Maria De Santis, et al.
Page
of 17
Search research articles
Search
Showing results (41-50 of 170) with videos related to
Sort By:
Page
of 17
Clinical & Developmental Immunology
|
July 24, 2013
JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?
Roberta Antonia Diotti, Akira Nakanishi, Nicola Clementi, et al.
International Journal of Molecular Sciences
|
June 19, 2024
Anti-HIV Humoral Response Induced by Different Anti-Idiotype Antibody Formats: An In Silico and In Vivo Approach
Valeria Caputo, Ilaria Negri, Louiza Moudoud, et al.
Journal of Medical Virology
|
March 9, 2023
Smallpox vaccination-elicited antibodies cross-neutralize 2022-Monkeypox virus Clade II
Elena Criscuolo, Benedetta Giuliani, Roberto Ferrarese, et al.
Antiviral Research
|
July 19, 2011
The new and less toxic protease inhibitor saquinavir-NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir
Filippo Canducci, Elisa Rita Ceresola, Diego Saita, et al.
AIDS Research and Human Retroviruses
|
January 13, 2004
Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure
Enzo Boeri, Nicola Gianotti, Filippo Canducci, et al.
The Journal of Antimicrobial Chemotherapy
|
December 21, 2002
Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients
Stefania Paolucci, Fausto Baldanti, Maurizio Zavattoni, et al.
The Journal of Infectious Diseases
|
October 11, 2011
Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir
Filippo Canducci, Elisa R Ceresola, Enzo Boeri, et al.
Virology
|
September 8, 2004
Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection
Roberto Burioni, Nicasio Mancini, Silvia Carletti, et al.
Viruses
|
June 24, 2022
Proper Selection of In Vitro Cell Model Affects the Characterization of the Neutralizing Antibody Response against SARS-CoV-2
Elena Criscuolo, Benedetta Giuliani, Davide Ferrari, et al.
Clinical Microbiology Reviews
|
April 1, 2021
Viral Respiratory Pathogens and Lung Injury
Nicola Clementi, Sreya Ghosh, Maria De Santis, et al.
Page
of 17